ATHIRA Trademark

Trademark Overview

On Thursday, March 28, 2019, a trademark application was filed for ATHIRA with the United States Patent and Trademark Office. The USPTO has given the ATHIRA trademark a serial number of 88361351. The federal status of this trademark filing is REGISTERED as of Tuesday, December 5, 2023. This trademark is owned by Athira Pharma, Inc.. The ATHIRA trademark is filed in the Pharmaceutical Products category with the following description:

Prescription pharmaceutical preparations, prescription pharmaceutical compounds in the nature of small molecule chemical compounds, and prescription pharmaceutical compositions for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, Stroke, Depression, Insomnia, Schizophrenia, Hearing Loss and Rheumatoid Arthritis
athira

General Information

Serial Number88361351
Word MarkATHIRA
Filing DateThursday, March 28, 2019
Status700 - REGISTERED
Status DateTuesday, December 5, 2023
Registration Number7236684
Registration DateTuesday, December 5, 2023
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 8, 2020

Trademark Statements

Goods and ServicesPrescription pharmaceutical preparations, prescription pharmaceutical compounds in the nature of small molecule chemical compounds, and prescription pharmaceutical compositions for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, Stroke, Depression, Insomnia, Schizophrenia, Hearing Loss and Rheumatoid Arthritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 16, 2019
Primary Code005
First Use Anywhere DateThursday, September 17, 2020
First Use In Commerce DateThursday, September 17, 2020

Trademark Owner History

Party NameAthira Pharma, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBothell, US 98011
Party NameAthira Pharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBothell, US 98011
Party NameAthira Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, US 981952141

Trademark Events

Event DateEvent Description
Monday, April 1, 2019NEW APPLICATION ENTERED
Tuesday, April 16, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 7, 2019ASSIGNED TO EXAMINER
Wednesday, June 12, 2019NON-FINAL ACTION WRITTEN
Wednesday, June 12, 2019NON-FINAL ACTION E-MAILED
Wednesday, June 12, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 11, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 11, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 12, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 15, 2020FINAL REFUSAL WRITTEN
Wednesday, January 15, 2020FINAL REFUSAL E-MAILED
Wednesday, July 15, 2020EXPARTE APPEAL RECEIVED AT TTAB
Wednesday, January 15, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, July 15, 2020JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, July 15, 2020EX PARTE APPEAL-INSTITUTED
Wednesday, July 15, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, July 29, 2020ASSIGNED TO LIE
Wednesday, July 29, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 29, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 4, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 4, 2020EXPARTE APPEAL TERMINATED
Wednesday, August 19, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 8, 2020PUBLISHED FOR OPPOSITION
Tuesday, September 8, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 3, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, April 29, 2021SOU TEAS EXTENSION RECEIVED
Thursday, April 29, 2021SOU EXTENSION 1 FILED
Thursday, April 29, 2021SOU EXTENSION 1 GRANTED
Saturday, May 1, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 13, 2021SOU TEAS EXTENSION RECEIVED
Thursday, March 24, 2022SOU EXTENSION 3 FILED
Monday, September 13, 2021SOU EXTENSION 2 FILED
Monday, September 13, 2021SOU EXTENSION 2 GRANTED
Wednesday, September 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 24, 2022SOU TEAS EXTENSION RECEIVED
Thursday, March 24, 2022SOU EXTENSION 3 GRANTED
Saturday, March 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 13, 2022SOU TEAS EXTENSION RECEIVED
Thursday, October 13, 2022SOU EXTENSION 4 FILED
Thursday, October 13, 2022SOU EXTENSION 4 GRANTED
Saturday, October 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 18, 2023SOU TEAS EXTENSION RECEIVED
Thursday, April 20, 2023TEAS STATEMENT OF USE RECEIVED
Thursday, April 20, 2023SOU EXTENSION 5 FILED
Thursday, April 20, 2023USE AMENDMENT FILED
Monday, May 8, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, May 9, 2023SOU EXTENSION 5 GRANTED
Tuesday, May 9, 2023STATEMENT OF USE PROCESSING COMPLETE
Wednesday, May 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 11, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, May 11, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 11, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, November 2, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, November 3, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, December 5, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, December 5, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

athira pharmaceutical prescription disease compounds neuropathy neuropathic multiple pain parkinson sclerosis